CASTEL SAN PIETRO, 8 October 2019 - Medacta International has recently obtained CE marking for the lateralized glenosphere. This new implant further expands the Medacta offering for shoulder arthroplasty, which now features a broader range of options for reverse shoulder replacement surgery.
The Medacta Shoulder System is a modular solution that includes wide-ranging sizes, adjustable offset and innovative configurations both in the anatomic and reverse configuration. It is compatible with, and can be further enhanced by, the CT-based MyShoulder 3D preoperative planning solution, offering patient-specific humeral and glenoid guides.
The lateralized glenosphere features a more lateralized centre of rotation compared to the standard glenosphere already included in the Medacta Shoulder System offering. The potential benefits are an improved range of motion, as well as a reduced risk of scapular notching.
This new CE mark clearance exemplifies Medacta's continuous commitment to leverage expertise gained throughout orthopaedics for the development of exceptional shoulder solutions.
For more information on Medacta Shoulder System and Medacta's shoulder arthroplasty solutions, visit https://www.medacta.com/EN/global-shoulder.
Document title: Medacta Receives CE Marking for the Lateralized Glenosphere
Issuer: Medacta Group SA
Key word(s): Advertisement/Communication
End of Corporate News
|Company:||Medacta Group SA|
|6874 Castel San Pietro|
|Phone:||+41 696 6060|
|Listed:||SIX Swiss Exchange|
|EQS News ID:||887253|
|End of News||EQS Group Media|